This is a working overview of Epitalon, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-28 and is reviewed periodically as new material appears.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
In its supplied form epitalon is a white to off-white powder, usually lyophilized and often hygroscopic. It dissolves readily in water and in aqueous buffers, and it is commonly handled as the acetate or trifluoroacetate salt to improve stability during purification and drying. The amide backbone is labile in aqueous media, so solutions are less durable than the dry solid. Handling notes in the chemical literature therefore emphasize keeping the powder dry, cool and shielded from light until it is dissolved.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four residues, linear chain |
| Residue sequence | Ala-Glu-Asp-Gly | Single-letter form AEDG |
| Calculated mass | 390.3 daltons | Value for the free, uncharged form |
| Appearance | White to off-white powder | Usually supplied lyophilized |
| Solubility | Freely soluble in water | Often handled as a salt form |
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The most frequently cited proposed action is induction of telomerase, the enzyme that adds repeat sequences to chromosome ends. Cell-culture work from the originating group reported higher telomerase reverse transcriptase expression and measurable telomere elongation in human somatic cells after exposure. How a four-residue peptide would reach nuclear gene regulation is not established, and no cell-surface receptor or uptake route has been identified. Additional reports describe changes in melatonin secretion, antioxidant enzyme activity and lipid peroxidation in aged animals, but these findings remain mechanistically unconnected to the telomerase observation.
Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.
== See also == Child-resistant packaging Codex Alimentarius Track and trace Product recall Contract manufacturing organization European Pharmacopoeia ClearRx Unit-dose packaging Validation (drug manufacture)
=== In the digestive system === In the digestive system, VIP seems to induce smooth muscle relaxation (lower esophageal sphincter, stomach, gallbladder), stimulate secretion of water into pancreatic juice and bile, and cause inhibition of gastric acid secretion and absorption from the intestinal lumen. Its role in the intestine is to greatly stimulate secretion of water and electrolytes, as well as relaxation of enteric smooth muscle, dilating peripheral blood vessels, stimulating pancreatic bicarbonate secretion, and inhibiting gastrin-stimulated gastric acid secretion. These effects work together to increase motility. It also has the function of stimulating pepsinogen secretion by chief cells. VIP seems to be an important neuropeptide during inflammatory bowel diseases since the communication between mast cells and VIP in colitis, as in Crohn's disease, is upregulated.
Pelage Pharmaceuticals presented on suvomipic at the American Academy of Dermatology (AAD) Annual Meeting 2026 in March 2026, including disclosing some new phase 2a trial data, but did not provide the open-label extension data at this event. Phase 3 trials of suvomipic for alopecia are being planned for 2026. It has been estimated that if suvomipic is successful in clinical trials and passes regulatory scrutiny, the drug could be approved for the treatment of hair loss sometime between 2027 and 2029 at the earliest. Suvomipic is currently Pelage Pharmaceuticals's only official drug candidate. However, the company is also investigating reactivation of dormant stem cells for treatment of other medical conditions. Pelage Pharmaceuticals had raised more than $30 million by August 2025, with investment being led by Google Ventures of Alphabet. In October 2025, it was announced that the company had raised $120 million. In 2019, Pelage Pharmaceuticals had reached an agreement that granted Allergan (now AbbVie) an option to acquire the startup company, but this deal was terminated in 2020. Suvomipic may also have applications in the treatment of other forms of hair loss besides androgenic alopecia. In October 2025, Time magazine named suvomipic one of the best inventions of 2025. However, the magazine also disclosed, via communication with Pelage Pharmaceuticals, that suvomipic may not be effective in the end stages of balding if the hair follicle is "scarred".
Escitalopram discontinuation, particularly abruptly, may cause certain withdrawal symptoms such as "electric shock" sensations, colloquially called "brain shivers" or "brain zaps" by those affected. Frequent symptoms in one study were dizziness (44%), muscle tension (44%), chills (44%), confusion or trouble concentrating (40%), amnesia (28%), and crying (28%). Very slow tapering is recommended. There have been spontaneous reports of discontinuation of escitalopram and other SSRIs and SNRIs, especially when abrupt, leading to dysphoric mood, irritability, agitation, anxiety, headache, lethargy, emotional lability, insomnia, and hypomania. Other symptoms such as panic attacks, hostility, aggression, impulsivity, akathisia (psychomotor restlessness), mania, worsening of depression, and suicidal ideation can emerge when the dose is adjusted down.
In addition, Marcos limited his position on the matter through oral statements and avoided issuing an executive order formalizing his stance. There were also unconfirmed reports, including by former Senator Antonio Trillanes, stating that ICC members had already entered the Philippines and were already secretly conducting the investigation. A House probe initiated in April 2024 by Romualdez into a "status quo" agreement in the South China Sea Duterte made during his presidency with Chinese president Xi Jinping was also seen as a "political payback" to Duterte's verbal attacks on Marcos and diminish Duterte's political influence ahead of the 2025 midterm elections. Amidst growing isolation, Duterte found allies who were previously loyal to Marcos. Among them were Marcos' longtime lawyer, Vic Rodriguez, who served as executive secretary in Marcos' first 79 days before resigning; and Marcos' sister, Senator Imee Marcos. On March 11, 2025, Duterte was arrested upon his arrival at Ninoy Aquino International Airport by the Filipino police, which enforced an arrest warrant issued by the International Criminal Court.
Sources: en.wikipedia.org
== Reception == For his portrayal of Ari, Kipa-Williams received a nomination for Best Daytime Star at the 2020 Inside Soap Awards. A writer for TVNZ was "thrilled" with the introduction of the Parata family and their connection to New Zealand. They believed that the family would "embody a taste of home, and we can't wait to see what Summer Bay has in store for them!" Kerry Harvey of Stuff pointed out that Paratas were "being hailed as New Zealand's answer to the show's much-loved River Boys". Bethany Reitsma of The New Zealand Herald believed that the Paratas would bring "a taste of classic Kiwi humour" to Home and Away. She also reported that New Zealand viewers were excited about a "Kiwi family" joining the show. Nick Everard and Jenny Ky from The Morning Show stated the Parata's arrival "rocked" Home and Away and their addition made "Summer Bay sizzle – and the fans can't get enough." Rachel Lucas from What's on TV observed that Ari "certainly makes an impact during the hospital siege". While an Inside Soap columnist joked "If he's looking for peace and quiet, Ari has come to the wrong place! His new life in the Bay will probably turn out to be even more dramatic than the past he’s running from". Tahlia Pritchard from Punkee enjoyed Tane and Ari facing off against each other, calling it "the most compelling TV I've watched all iso." She also thought it was "hot" and found Tane and Ari to be "reminiscent of the River Boys but, well, sexier and with no shit tattoos." Stephanie McKenna of The West Australian branded Ari a "popular character".
==== Detoxification and drug metabolism ==== Enzymes such as CYP3A4, along with the antiporter activities, are also instrumental in the intestine's role of drug metabolism in the detoxification of antigens and xenobiotics.
He also notes a venom yield of 200–411 mg. Human envenoming by this species, although infrequent, can be rather severe due to the large volumes of venom injected. Envenomation is characterized by pronounced local tissue damage and systemic dysfunctions, including massive internal bleeding.
The Southern Rhodesians claimed that Butler justified his refusal to give a written promise by saying that binding Whitehall to a document rather than his word would be against the Commonwealth's "spirit of trust"—an argument that Field eventually accepted. "Let's remember the trust you emphasised", Smith warned, according to Field's account wagging his finger at Butler; "if you break that you will live to regret it." Southern Rhodesia attended the conference, which was held at Victoria Falls over a week starting from 28 June 1963, and among other things it was agreed to formally liquidate the Federation at the end of the year. In the House of Commons afterwards, Butler flatly denied suggestions that he had "oiled the wheels" of Federal dissolution with secret promises to the Southern Rhodesians. Field's government was startled by Britain's announcement in October 1963 that Nyasaland would become fully independent on 6 July 1964. While no date was set for Northern Rhodesian statehood, it was generally surmised that it was going to follow shortly thereafter. Smith was promptly sent to London, where he held a round of inconclusive Southern Rhodesian independence talks with the new British Prime Minister, Sir Alec Douglas-Home.
Sources: en.wikipedia.org
The peptide contains four residues in the order alanine, glutamate, aspartate and glycine, abbreviated AEDG. The chain is linear and held together by three peptide bonds. Its calculated mass for the uncharged free form is about 390.3 daltons.
Epithalamin refers to a crude preparation derived from bovine pineal tissue, which contains many components. Epitalon is a single synthetic tetrapeptide identified from that material and produced by chemical synthesis. The two names are sometimes confused because early reports treated the synthetic peptide as an active fragment of the extract.
It has been registered for clinical use in Russia, where it is associated with a small family of short peptides. In most other jurisdictions it is not an approved medicine and is traded as a research chemical. Regulatory status varies by country and changes over time.
It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.